The DOI matches its Crossref record.
Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia
Open accessAbstract
Hepatitis C virus (HCV)‐associated mixed cryoglobulinemia (MC) vasculitis commonly regresses upon virus eradication, but conventional therapy with pegylated interferon and ribavirin yields approximately 40% sustained virologic responses (SVR). We prospectively evaluated the efficacy and safety of sofosbuvir‐based direct‐acting antiviral therapy, individually tailored according to the latest guidelines, in a cohort of 44 consecutive patients with HCV‐associated MC. In two patients MC had evolved into an indolent lymphoma with monoclonal B‐cell lymphocytosis. All patients had negative HCV viremia at week 12 (SVR12) and at week 24 (SVR24) posttreatment, at which time all had a clinical response of vasculitis. The mean (±standard deviation) Birmingham Vasculitis Activity Score decreased from 5.41 (±3.53) at baseline to 2.35 (±2.25) ( P < 0.001) at week 4 on treatment to 1.39 (±1.48) ( P < 0.001) at SVR12 and to 1.27 (±1.68) ( P < 0.001) at SVR24. The mean cryocrit value fell from 7.2 (±15.4)% at baseline to 2.9 (±7.4)% ( P < 0.01) at SVR12 and to 1.8 (±5.1)% ( P < 0.001) at SVR24. Intriguingly, in the 2 patients with MC and lymphoma there was a partial clinical response of vasculitis and ∼50% decrease of cryocrit, although none experienced a significant decrease of monoclonal B‐cell lymphocytosis. Adverse events occurred in 59% of patients and were generally mild, with the exception of 1 patient with ribavirin‐related anemia requiring blood transfusion. Conclusion: Interferon‐free, guideline‐tailored therapy with direct‐acting antivirals is highly effective and safe for HCV‐associated MC patients; the overall 100% rate of clinical response of vasculitis, on an intention‐to‐treat basis, opens the perspective for curing the large majority of these so far difficult‐to‐treat patients. (H epatology 2016;64:1473‐1482)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Muchtar, E., Magen, H., & Gertz, M. A. (2017) · Blood · doi:10.1182/blood-2016-09-719773 · Cited by 190
Metadata
- Authors
- Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., Perez, M., Ceccotti, G., Colantuono, S., Mitrevski, M., Stasi, C., Del Padre, M., Monti, M., Gianni, E., Pulsoni, A., Fiorilli, M., Casato, M., & Zignego, A. L.
- Venue
- Hepatology
- Published
- 2016-08-29
- Volume
- 64
- Issue
- 5
- Pages
- 1473-1482
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2495198776
- Cited by
- 211
- References
- 0
- FWCI
- 20.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia. https://app.cochat.ai/papers/10.1002/hep.28753
- The paper
- Gragnani, L., Visentini, M., Fognani, E., Urraro, T., De Santis, A., Petraccia, L., Perez, M., Ceccotti, G., Colantuono, S., Mitrevski, M., Stasi, C., Del Padre, M., Monti, M., Gianni, E., Pulsoni, A., Fiorilli, M., Casato, M., & Zignego, A. L. (2016). Prospective study of guideline‐tailored therapy with direct‐acting antivirals for hepatitis C virus‐associated mixed cryoglobulinemia. Hepatology. https://doi.org/10.1002/hep.28753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.